International journal of laboratory hematology · 2026
Role of Flow Cytometric Enumeration of Circulating hMICL (CD371) Positive Leukemic Stem Cells in Diagnosis and Prognostication of BCR::ABL1-Negative Myeloproliferative Neoplasms.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oberoi Gurleen, Dhawan Rishi, Dass Jasmita, Ganju Neha, Viswanathan Ganesh, Lata Suman, Agarwal Mukul, Kumar Pradeep Kumar, Seth Tulika, Mahapatra Manoranjan, Saxena Renu
Аннотация
BACKGROUND: BCR-ABL1-negative myeloproliferative neoplasms (MPNs) often exhibit overlapping clinical and morphological features, making accurate subcategorization challenging. The h-MICL (CD371) antigen, selectively expressed on leukemic stem cells (LSCs) and absent on CD34+CD38- cells in normal or regenerating marrow, represents a potential diagnostic and prognostic marker.
OBJECTIVES: This study aimed to evaluate the diagnostic utility of circulating CD34+CD38-h-MICL+ cells in subtyping BCR-ABL1-negative MPNs and to assess their correlation with the Dynamic International Prognostic Scoring System (DIPSS) score. Additionally, to identify a cut-off value of CD34+CD38-h-MICL+ cells that can effectively differentiate PMF.
METHODS: Fifty-four patients with BCR-ABL1-negative MPNs were prospectively enrolled at a tertiary care center in North India over 18 months. Peripheral blood was analyzed via flow cytometry to quantify CD34+, CD34+CD38+, CD34+CD38-, and CD34+CD38-h-MICL+ cell subsets.
RESULTS: A significant increase in circulating CD34+CD38-h-MICL+ cells was observed in patients with overt MF (median 2.8%), prefibrotic MF (4.15%), and post-PV/ET MF (3%) compared to PV and ET (median 0%; p < 0.001). A threshold of ≥ 0.9% CD34+CD38-h-MICL+ cells effectively identified MF cases with 88% sensitivity and 89% specificity. Moreover, a positive correlation was found between the percentage of CD34+CD38-h-MICL+ cells and DIPSS score (ρ = 0.41, p = 0.036), with every 1.72% increase in this cell population corresponding to a 1-point rise in DIPSS score.
CONCLUSION: Circulating CD34+CD38-h-MICL+ cells represent a promising biomarker; their quantification may aid in subclassification, particularly in distinguishing prefibrotic MF from ET, and may serve as a potential target for future therapeutic strategies. Further validation in larger cohorts is warranted.
OBJECTIVES: This study aimed to evaluate the diagnostic utility of circulating CD34+CD38-h-MICL+ cells in subtyping BCR-ABL1-negative MPNs and to assess their correlation with the Dynamic International Prognostic Scoring System (DIPSS) score. Additionally, to identify a cut-off value of CD34+CD38-h-MICL+ cells that can effectively differentiate PMF.
METHODS: Fifty-four patients with BCR-ABL1-negative MPNs were prospectively enrolled at a tertiary care center in North India over 18 months. Peripheral blood was analyzed via flow cytometry to quantify CD34+, CD34+CD38+, CD34+CD38-, and CD34+CD38-h-MICL+ cell subsets.
RESULTS: A significant increase in circulating CD34+CD38-h-MICL+ cells was observed in patients with overt MF (median 2.8%), prefibrotic MF (4.15%), and post-PV/ET MF (3%) compared to PV and ET (median 0%; p < 0.001). A threshold of ≥ 0.9% CD34+CD38-h-MICL+ cells effectively identified MF cases with 88% sensitivity and 89% specificity. Moreover, a positive correlation was found between the percentage of CD34+CD38-h-MICL+ cells and DIPSS score (ρ = 0.41, p = 0.036), with every 1.72% increase in this cell population corresponding to a 1-point rise in DIPSS score.
CONCLUSION: Circulating CD34+CD38-h-MICL+ cells represent a promising biomarker; their quantification may aid in subclassification, particularly in distinguishing prefibrotic MF from ET, and may serve as a potential target for future therapeutic strategies. Further validation in larger cohorts is warranted.